Newsletters and Deep Dive digital magazine
UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi
UK-listed Hikma Pharma has licensed an array of injectable cancer drugs from China’s Hansoh, sparking a rise in its share price.
Hikma has a new chief executive after Said Darwazah, the son of the company’s late founder, Samih Darwazah, stepped aside.
While Sandoz has emerged as the front-runner to get a generic version of GlaxoSmithKline’s respiratory blockbuster Advair to the US market, rival Hikma has not given up despite a major setb
Last year, GSK said it was planning to invest a cool £1 billion in infectious d
What does it take to establish new treatments for rare diseases?